Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -49.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $179M | $97M | $215M | $991M | $1.1B | $3.6B | $2.1B | — | — |
| Enterprise Value | $183M | $101M | $224M | $1.0B | $1.1B | $3.6B | $2.1B | — | — |
| P/E Ratio → | -1.32 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 3.19 | — | — | — | — | — | — |
| P/B Ratio | 0.84 | 0.45 | 0.64 | 2.27 | 2.45 | 9.85 | 6.39 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 3.32 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | -283.6% | — | — | — | — | — | -169878.6% |
| Net Profit Margin | — | — | -246.0% | — | — | — | — | — | -150478.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.5% | -49.5% | -42.8% | -67.1% | -59.3% | -45.5% | -58.7% | -90.7% | -65.2% |
| ROA | -38.1% | -38.1% | -33.4% | -52.4% | -46.2% | -37.9% | -51.9% | -70.7% | -51.4% |
| ROIC | -40.5% | -40.5% | -35.8% | -50.3% | -43.2% | -51.5% | -62.7% | -650.4% | -249.4% |
| ROCE | -48.5% | -48.5% | -43.9% | -60.5% | -49.1% | -56.6% | -57.9% | -86.6% | -68.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.13 | 0.10 | 0.11 | 0.13 | 0.01 | 0.04 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | 0.03 | 0.04 | 0.01 | -0.04 | -0.16 | -0.95 | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -91.26 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Quick Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Cash Ratio | 6.73 | 6.73 | 7.04 | 6.96 | 7.72 | 7.74 | 11.84 | 4.51 | 4.05 |
| Asset Turnover | — | — | 0.16 | — | — | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 27.07 | — | — | — | — | — | 23907.50 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $72M | $71M | $65M | $53M | $43M | $41M | $36M | $18M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZNTL stock.
Zentalis Pharmaceuticals, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
Zentalis Pharmaceuticals, Inc.'s return on equity (ROE) is -49.5%. The historical average is -59.8%.
Based on historical data, Zentalis Pharmaceuticals, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Clinical hold and liquidity
Metrics are mathematically derived from official filings.
Binary Outcomes Drive Valuation Multiples
As reported in financial statements, ZNTL's forward EV/EBITDA of 226.47 suggests that the market is pricing the company based on speculative future clinical success rather than current fundamentals, reflecting a high-risk valuation profile that is significantly detached from the company's current lack of commercial revenue or earnings.
The extreme forward multiple indicates that investors are assigning value almost exclusively to the potential of azenosertib, effectively ignoring the current negative earnings and cash burn. This valuation appears highly sensitive to clinical trial readouts, as any delay or safety signal likely triggers a significant re-rating of the stock's implied growth trajectory.
Capital Compounding Remains Deeply Negative
Based on ZNTL's reported figures, the ROIC has consistently trended in negative territory, reaching -14.0% in 2026Q1, which highlights the company's inability to generate productive returns on the capital deployed into its extensive and costly oncology research and development pipeline over the past several quarters.
The persistent negative ROIC reflects a structural mismatch between the massive capital requirements of clinical-stage biotechnology and the absence of any revenue-generating assets. This trend suggests that shareholders are currently funding a value-destructive phase of development that requires a successful regulatory approval to reverse the long-term decay in capital efficiency.
Liquidity Buffer Nearing Critical Threshold
According to recent SEC filings, the company's current ratio of 6.19 in 2026Q1, while appearing superficially high, masks a rapidly depleting cash position that leaves the firm with a dangerously narrow runway to sustain its ongoing clinical trial operations without immediate access to additional dilutive capital markets.
The high current ratio is largely a function of the company's remaining cash reserves relative to its current liabilities, but the absolute dollar amount of liquidity is insufficient to support the current burn rate for an extended period. Investors should monitor the cash runway closely, as the current liquidity position appears inadequate to survive a prolonged FDA clinical hold or further delays in trial enrollment.
Misapplication of Traditional Valuation Metrics
Based on the provided data, the most commonly misapplied metric for ZNTL is the P/E ratio, which obscures the company's true economic reality by focusing on accounting losses that are inherent to the clinical-stage biotech business model rather than reflecting the underlying value of the drug pipeline.
Using P/E to evaluate a pre-revenue firm like ZNTL is fundamentally flawed because it treats R&D expenses as a recurring operational cost rather than a capital investment in future intellectual property. Analysts should instead focus on cash runway and probability-adjusted net present value (rNPV) of the pipeline to better capture the company's potential value.